Thrombin activatable fibrinolysis inhibitor in Behcet's disease


Donmez A., Aksu K. , Celik H. , Keser G., Cagirgan S., Omay S., ...Daha Fazla

THROMBOSIS RESEARCH, cilt.115, ss.287-292, 2005 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 115 Konu: 4
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1016/j.thromres.2004.09.010
  • Dergi Adı: THROMBOSIS RESEARCH
  • Sayfa Sayıları: ss.287-292

Özet

Introduction: Thrombin activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase downregulating plasmin formation, thereby causing a tendency for thrombosis development. Since, Behcet's disease (BD) is a systemic vasculitis, which is commonly complicated by arterial and venous thrombosis, we aimed to find out plasma TAR levels in BD, compared with healthy controls. We also searched whether plasma TAFI levels were significantly different between Behcet's subgroups with and without thrombosis.